Methods for identifying compositions for inhibiting viral infectivity
AssigneeMeharry Medical College
InventorBindong Liu
Life of this patent
Estimating the term…
Abstract
Compositions that inhibit the HIV-1 viral infectivity factor (Vif) and methods of use thereof are provided. The disclosed compositions have inhibitory activity against Vif function and restore A3G enzymatic activity. The disclosed compositions may be used to treat and/or prevent infection and transmission of viruses (such as HIV), to inhibit the function of Vif in a cell, to inhibit viral infectivity in a cell, and to inhibit replication of a virus. Methods of identifying Vif inhibitors are also provided.
Claims67
A method of making a derivative of cefixime having an inhibitory effect on HIV-1 viral infectivity factor (Vif), comprising:
- providing cefixime;
- dissolving the cefixime in a solvent to form a cefixime/solvent mixture;
- and
- incubating the cefixime/solvent mixture at a temperature of about 37° C. to about 110° C. for about five days to about 30 days to form the derivative of cefixime having an inhibitory effect on Vif.
A method for identifying a compound that inhibits Vif function, comprising:
- providing a mixture comprising
- an amount of A3G,
- an amount of Vif, and
- an amount of an oligonucleotide having a CCC sequence or a CC sequence;
- contacting the mixture with a compound to form a sample;
- measuring a conversion of the oligonucleotide having a CCC sequence or a CC sequence in the sample to an oligonucleotide having a CCU sequence or a CU sequence;
- and
- determining the compound is capable of inhibiting Vif function based on the measurement of the conversion of the oligonucleotide having a CCC sequence or a CC sequence to the oligonucleotide having the CCU sequence or the CU sequence.
An assay for identifying a compound that has an inhibitory effect on Vif, comprising:
- providing a mixture comprising
- an amount of A3G,
- an amount of Vif, and
- an amount of an oligonucleotide having a CCC sequence or CC sequence;
- contacting the mixture with a compound to form a sample;
- measuring a conversion of the oligonucleotide having a CCC sequence or CC sequence in the sample to an oligonucleotide having a CCU sequence or CU sequence;
- and
- determining the compound is capable of inhibiting Vif function based on the measurement of the conversion of the oligonucleotide having a CCC sequence or CC sequence to the oligonucleotide having the CCU sequence or CU sequence.
A kit for identifying a compound that inhibits Vif, comprising:
- an amount of A3G,
- an amount of Vif, and
- an amount of an oligonucleotide having a CCC sequence or CC sequence.
Dependencies are inferred from the claim text.